{"hands_on_practices": [{"introduction": "Understanding the functional state of the complement system is a cornerstone of both clinical immunology and basic research. This first exercise challenges you to master the principles behind the classic CH50 and AH50 hemolytic assays, which provide a global view of complement pathway integrity. By working through the logic of how these assays isolate the classical and alternative pathways, you will build a foundational skill in interpreting functional data to pinpoint specific defects or consumption patterns within the cascade. [@problem_id:2836561]", "problem": "A researcher aims to evaluate the functional integrity of the complement system in patient serum using hemolytic assays that reflect pathway-specific activation leading to formation of the membrane attack complex (MAC). The complement system has three initiation routes—classical, lectin, and alternative pathways—that converge on cleavage of complement component C3, followed by C5 cleavage and assembly of C5-C9 (the MAC), which can lyse target membranes such as red blood cells (RBCs). In the classical pathway, antibody-bound targets trigger the C1 complex; in the lectin pathway, mannose-binding lectin (MBL) and associated serine proteases recognize carbohydrate patterns; and in the alternative pathway, continuous low-rate spontaneous hydrolysis of C3 (so-called tick-over) amplifies on surfaces that lack regulators. Hemolytic assays quantify the ability of serum to lyse erythrocytes under conditions that isolate classical versus alternative activation, and the readout is defined as the serum dilution that yields 50% lysis.\n\nConsider the following statements about the principles and readouts of the classical pathway 50% hemolytic activity (CH50) assay and the alternative pathway 50% hemolytic activity (AH50) assay, and what patterns of results reveal about pathway integrity. Select all statements that are accurate.\n\nA. The CH50 assay uses antibody-sensitized sheep RBCs and a buffer supplying $Ca^{2+}$; the titer is the reciprocal of the highest serum dilution causing 50% hemolysis. An undetectable CH50 with a normal AH50 indicates a defect in early classical components such as C2 or C4.\n\nB. The AH50 assay isolates the alternative pathway by using rabbit RBCs in a buffer containing ethylenediaminetetraacetic acid (EDTA) to chelate $Mg^{2+}$; a normal AH50 with a low CH50 indicates a deficiency in C5-C9.\n\nC. Because both assays require C3 cleavage and MAC formation to lyse RBCs, deficiencies in C3 or in terminal components C5-C9 lower both CH50 and AH50.\n\nD. Lectin pathway function is directly measured by CH50 because mannose-binding lectin (MBL) can substitute for antibody on sheep RBCs; therefore, an isolated MBL deficiency typically produces a low CH50 with a normal AH50.\n\nE. In the AH50 assay, ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA) with excess $Mg^{2+}$ is used to chelate $Ca^{2+}$ and suppress the classical and lectin pathways while preserving the alternative pathway; a low AH50 with a normal CH50 suggests a defect in properdin, factor B, or factor D.\n\nChoose all that apply.", "solution": "To reason from first principles, begin with the core definitions and requirements of complement-mediated hemolysis. All complement activation routes converge on formation of a C3 convertase that cleaves C3 into C3a and C3b, followed by C5 convertase formation and cleavage of C5 to initiate assembly of the membrane attack complex (MAC; C5-C9). Hemolysis of erythrocytes requires completion of the cascade through MAC insertion. Therefore, any hemolytic readout intrinsically depends on the presence and function of C3 and the terminal pathway components C5-C9. The classical pathway requires $Ca^{2+}$ for the C1 complex (C1q, C1r, C1s) to be functional. The alternative pathway requires $Mg^{2+}$ and is promoted on activating surfaces such as rabbit RBCs and is inhibited by chelation of $Mg^{2+}$; it is not dependent on $Ca^{2+}$ in the same way that the classical and lectin pathways are. The lectin pathway is structurally analogous to the classical pathway but uses MBL and MBL-associated serine proteases rather than antibodies and C1.\n\nPrinciples of the assays: The CH50 assay measures classical pathway–dependent hemolysis using antibody-sensitized sheep RBCs in a buffer containing $Ca^{2+}$ (and typically $Mg^{2+}$), and reports the serum dilution causing 50% lysis. The AH50 assay measures alternative pathway–dependent hemolysis using rabbit RBCs in a buffer with $Mg^{2+}$-EGTA, where ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA) selectively chelates $Ca^{2+}$ while allowing $Mg^{2+}$ to remain available, thereby suppressing $Ca^{2+}$-dependent classical and lectin activation and isolating alternative pathway activity. In contrast, ethylenediaminetetraacetic acid (EDTA) chelates both $Ca^{2+}$ and $Mg^{2+}$ and would suppress all complement hemolysis.\n\nInterpretation patterns from these principles:\n- Low CH50 with normal AH50 indicates an early classical pathway defect (for example, C1 components, C2, or C4), because the alternative pathway remains competent.\n- Low AH50 with normal CH50 indicates an alternative pathway defect (for example, properdin, factor B, or factor D).\n- Low values for both assays indicate defects common to both pathways (for example, C3 or terminal components C5-C9), or global complement consumption.\n\nEvaluate each option:\n\nA. Accurate on all points. CH50 uses antibody-coated sheep RBCs with $Ca^{2+}$ present; the result is expressed as the reciprocal of the highest dilution that yields 50% lysis. An undetectable CH50 with a normal AH50 is the expected pattern for early classical pathway defects such as C2 or C4. Verdict — Correct.\n\nB. The buffer described is incorrect: EDTA chelates both $Ca^{2+}$ and $Mg^{2+}$ and would inhibit alternative pathway activity, abolishing hemolysis rather than isolating it. Furthermore, a normal AH50 with a low CH50 does not indicate a terminal pathway deficiency, because deficiencies in C5-C9 would depress both assays due to failure to form the MAC. Verdict — Incorrect.\n\nC. This follows directly from the requirement that both assays depend on C3 activation and MAC formation for hemolysis. Deficiency in C3 or in C5-C9 reduces both CH50 and AH50. Verdict — Correct.\n\nD. CH50 is not a direct assay of the lectin pathway; it is driven by antibody-sensitized targets and the C1 complex. MBL does not substitute for antibody in the standard CH50 assay, and isolated MBL deficiency typically leaves CH50 normal. Dedicated lectin pathway functional assays are required to assess MBL pathway activity. Verdict — Incorrect.\n\nE. The buffer principle is correct: $Mg^{2+}$-EGTA chelates $Ca^{2+}$ to suppress classical and lectin pathways while supplying $Mg^{2+}$ to permit alternative activation. A low AH50 with a normal CH50 is the expected pattern for defects in alternative pathway components such as properdin, factor B, or factor D. Verdict — Correct.\n\nTherefore, the correct choices are A, C, and E.", "answer": "$$\\boxed{ACE}$$", "id": "2836561"}, {"introduction": "Moving from foundational assays to clinical application, this problem places you in the role of a consulting immunologist faced with a complex case of acute kidney injury. The challenge is to synthesize a patient's clinical history with a full panel of complement laboratory data, including the C3 and C4 levels alongside the functional CH50 and AH50 assays. This practice is designed to hone your diagnostic reasoning skills, demonstrating how specific patterns of complement consumption can definitively point to the underlying pathophysiology driving a disease process. [@problem_id:2836540]", "problem": "A $17$-year-old previously healthy male presents with new-onset gross hematuria and periorbital edema $2$ weeks after a pharyngitis. Vital signs are stable; there is no rash or arthritis. Urinalysis shows $3+$ blood and red blood cell casts. The following complement studies are obtained with reference ranges provided:\n\n- Complement component $3$ (C3): $38$ mg/dL (reference $90$–$180$ mg/dL)\n- Complement component $4$ (C4): $26$ mg/dL (reference $10$–$40$ mg/dL)\n- Total hemolytic complement (CH50): $12$ U/mL (reference $60$–$140$ U/mL)\n- Alternative pathway hemolytic complement (AH50): $9$ U/mL (reference $60$–$140$ U/mL)\n\nWhich option best identifies the predominantly involved complement pathway and proposes a scientifically coherent differential diagnosis that includes both genetic deficiencies and consumption states?\n\nA. Predominant alternative pathway activation and consumption; differential includes C3 glomerulopathy driven by C3 nephritic factor, complement factor H or factor I deficiency, and post-infectious glomerulonephritis\n\nB. Predominant classical pathway deficiency or consumption; differential includes C2 deficiency and active Systemic Lupus Erythematosus (SLE) flare\n\nC. Predominant terminal pathway deficiency; differential centers on inherited C5–C9 deficiency with recurrent Neisseria infections\n\nD. Predominant isolated classical pathway overactivation due to C1 inhibitor deficiency; differential includes hereditary angioedema and acquired C1 inhibitor deficiency\n\nE. Predominant alternative pathway component deficiency; differential includes factor B, factor D, or properdin deficiency with normal upstream components", "solution": "The problem statement will first be subjected to a rigorous validation process.\n\n**Step 1: Extract Givens**\n\n*   **Patient Demographics:** A $17$-year-old, previously healthy male.\n*   **Clinical Presentation:** New-onset gross hematuria and periorbital edema.\n*   **Temporal History:** Onset is $2$ weeks after a pharyngitis.\n*   **Physical Examination Findings:** Vital signs are stable; no rash or arthritis is present.\n*   **Urinalysis Results:** $3+$ blood and the presence of red blood cell casts.\n*   **Complement Laboratory Data (with reference ranges):**\n    *   Complement component $3$ (C3): $38$ mg/dL (reference $90$–$180$ mg/dL).\n    *   Complement component $4$ (C4): $26$ mg/dL (reference $10$–$40$ mg/dL).\n    *   Total hemolytic complement (CH50): $12$ U/mL (reference $60$–$140$ U/mL).\n    *   Alternative pathway hemolytic complement (AH50): $9$ U/mL (reference $60$–$140$ U/mL).\n\n**Step 2: Validate Using Extracted Givens**\n\n1.  **Scientific Groundedness:** The problem describes a classic clinical presentation of acute nephritic syndrome. The combination of recent pharyngitis, hematuria with red blood cell casts, and edema is a textbook scenario for post-infectious glomerulonephritis (PIGN), often post-streptococcal. The use of complement studies to investigate the underlying immunopathology of glomerulonephritis is a standard and fundamental practice in immunology and nephrology. The provided laboratory values are consistent with known patterns of complement activation in such diseases. The problem is firmly grounded in established medical science.\n2.  **Well-Posedness:** The problem provides a specific clinical context and a complete set of relevant laboratory data with reference ranges. The question asks for an interpretation of these data to identify the involved complement pathway and formulate a differential diagnosis. This is a well-defined task with a unique, scientifically supported solution.\n3.  **Objectivity:** The problem statement is composed of objective clinical observations and quantitative laboratory measurements. There are no subjective, ambiguous, or opinion-based statements.\n4.  **Completeness and Consistency:** The data are sufficient for a competent analysis. The clinical history (pharyngitis) and the lab profile (low C3, normal C4) are internally consistent and point toward a specific category of immunological pathology.\n\n**Step 3: Verdict and Action**\n\nThe problem statement is scientifically sound, well-posed, objective, and internally consistent. It represents a realistic and non-trivial diagnostic challenge. Therefore, the problem is **valid**. We may proceed to a full solution.\n\n**Principle-Based Derivation**\n\nThe complement system is a crucial part of the innate immune system. Its activation can occur via three primary pathways: the classical, lectin, and alternative pathways, all of which converge to cleave component C3 and activate the terminal pathway (C5-C9).\n\n1.  **The Classical Pathway** is typically initiated by antigen-antibody complexes. Its activation consumes early components C1q, C1r, C1s, C4, and C2, which then leads to the consumption of C3. Therefore, significant classical pathway activation is characterized by low levels of both C4 and C3.\n2.  **The Lectin Pathway** is initiated by the binding of mannose-binding lectin (MBL) to carbohydrates on pathogen surfaces. It also proceeds through cleavage of C4 and C2, leading to C3 consumption. Its activation profile, therefore, also involves low C4 and low C3.\n3.  **The Alternative Pathway** can be activated directly by certain pathogen surfaces or through spontaneous low-level hydrolysis of C3 (tick-over). It bypasses C1, C4, and C2, directly consuming C3 with the help of Factor B, Factor D, and Properdin. Therefore, isolated or predominant activation of the alternative pathway is characterized by **low C3 with a normal C4**.\n\nThe functional assays provided are:\n*   **CH50 (Total Hemolytic Complement):** This measures the function of the entire classical and terminal pathways. A low value indicates a deficiency or consumption of any component from C1 through C9.\n*   **AH50 (Alternative Pathway Hemolytic Complement):** This measures the function of the alternative and terminal pathways. A low value indicates a deficiency or consumption of an alternative pathway component (Factor B, Factor D, Properdin) or a shared terminal component (C3, C5-C9).\n\n**Analysis of Patient Data**\n\n*   **C3 = 38 mg/dL (low):** This indicates significant and ongoing complement activation leading to C3 consumption.\n*   **C4 = 26 mg/dL (normal):** This is the most discriminating finding. A normal C4 level effectively rules out significant activation of the classical or lectin pathways, as both would consume C4.\n*   **CH50 = 12 U/mL (low):** The classical pathway functional assay is low. Since the classical pathway itself is not being activated (normal C4), this low value must be due to the consumption of a downstream component shared by all pathways, namely C3. The profound depletion of C3 prevents the classical pathway from proceeding to completion in this *in vitro* assay.\n*   **AH50 = 9 U/mL (low):** The alternative pathway functional assay is low. This confirms that there is a defect in this pathway, which, in the context of a low C3, is due to consumption of alternative pathway components, including C3 itself.\n\n**Conclusion:** The aformentioned pattern—low C3, normal C4, low CH50, and low AH50—is the definitive signature of **predominant alternative pathway activation and consumption**.\n\nThe clinical presentation of acute nephritic syndrome following pharyngitis, coupled with this complement profile, directs the differential diagnosis towards conditions driven by alternative pathway dysregulation. This includes:\n1.  **Post-Infectious Glomerulonephritis (PIGN):** The most probable diagnosis in this context. Certain bacterial antigens can directly trigger and amplify the alternative pathway. The condition is typically self-limited.\n2.  **C3 Glomerulopathy (C3G):** A category of rare kidney diseases characterized by dysregulation of the alternative pathway. This can be caused by acquired factors (e.g., C3 nephritic factor, an autoantibody that stabilizes the alternative pathway C3-convertase) or genetic mutations in complement regulatory proteins (e.g., Factor H, Factor I). An acute infection can be a trigger that unmasks an underlying predisposition to C3G.\n\n**Option-by-Option Analysis**\n\n**A. Predominant alternative pathway activation and consumption; differential includes C3 glomerulopathy driven by C3 nephritic factor, complement factor H or factor I deficiency, and post-infectious glomerulonephritis**\nThis option correctly identifies the pathway based on the low C3 and normal C4 profile. The differential diagnosis provided is scientifically impeccable. It includes the most likely acute, consumption-driven state (PIGN) and correctly identifies the chronic/genetic states of alternative pathway dysregulation (C3G due to C3 nephritic factor, and deficiencies of the regulators Factor H or I) that present identically.\n**Verdict: Correct.**\n\n**B. Predominant classical pathway deficiency or consumption; differential includes C2 deficiency and active Systemic Lupus Erythematosus (SLE) flare**\nThis option is fundamentally flawed. Classical pathway activation is defined by consumption of C4. The patient's C4 level is normal. SLE nephritis typically presents with low C3 **and** low C4. An isolated C2 deficiency would cause a low CH50 but would not, in itself, cause consumption of C3. The patient's clinical signs (no rash, no arthritis) also argue against SLE.\n**Verdict: Incorrect.**\n\n**C. Predominant terminal pathway deficiency; differential centers on inherited C5–C9 deficiency with recurrent Neisseria infections**\nThis option is erroneous. An isolated deficiency of a terminal component (C5–C9) would result in a low CH50 and low AH50, as these assays cannot complete. However, the levels of upstream components, specifically C3 and C4, would be normal. This patient has a severely depleted C3. Furthermore, the clinical manifestation of terminal pathway deficiency is susceptibility to *Neisseria* infections, not glomerulonephritis.\n**Verdict: Incorrect.**\n\n**D. Predominant isolated classical pathway overactivation due to C1 inhibitor deficiency; differential includes hereditary angioedema and acquired C1 inhibitor deficiency**\nThis option is incorrect on multiple logical grounds. First, C1 inhibitor deficiency leads to uncontrolled cleavage of C4 and C2, resulting in a very low C4 level, which contradicts the patient's data. C3 is typically not consumed. Second, the clinical manifestation is angioedema due to bradykinin overproduction, not the nephritic syndrome seen in this patient. The periorbital edema here is due to renal fluid retention.\n**Verdict: Incorrect.**\n\n**E. Predominant alternative pathway component deficiency; differential includes factor B, factor D, or properdin deficiency with normal upstream components**\nThis option demonstrates a misunderstanding of complement pathology. A deficiency of an activating component of the alternative pathway (Factor B, D, or Properdin) would *impair* its function, not cause overactivation. Such a deficiency would lead to a low AH50 but would result in normal C3 levels, as the pathway would be unable to consume C3. The patient's data show profound C3 *consumption*, indicating pathway *overactivation*.\n**Verdict: Incorrect.**", "answer": "$$\\boxed{A}$$", "id": "2836540"}, {"introduction": "The ultimate goal of understanding disease mechanisms is to design effective therapies. This final practice challenges you to think strategically about therapeutic intervention, comparing the effects of blocking the complement cascade at two different key nodes: C3 and C5. By analyzing two distinct disease scenarios driven by different effector pathways, you will learn to rationally select a therapeutic target to maximize efficacy while anticipating and managing mechanism-based side effects. [@problem_id:2836510]", "problem": "A clinician is designing complement-targeted therapy for two distinct patients. Patient X has Paroxysmal Nocturnal Hemoglobinuria (PNH) with laboratory evidence of intravascular hemolysis and flow cytometry showing loss of complement regulators CD55 and CD59 on erythrocytes. Patient Y has an autoimmune hemolytic process dominated by extravascular clearance of red blood cells via complement opsonization; the Direct Antiglobulin Test (DAT) is positive for C3d on erythrocytes, and splenic macrophages show increased uptake of C3b-coated cells. The clinician wants to choose between inhibiting complement component C5 versus C3, and also to anticipate the most likely differences in infectious and immunopathologic risks across the two strategies. Based only on foundational definitions of complement activation (that is, that C3 cleavage yields the opsonin C3b and the anaphylatoxin C3a, and that C5 cleavage initiates assembly of the Membrane Attack Complex (MAC) through C5b-C9 leading to direct lysis, with C5a as a potent chemoattractant), which of the following strategies best aligns with the dominant pathophysiology in each patient and most accurately predicts differential side-effect profiles?\n\nA. Prefer C5 inhibition for Patient X to prevent MAC-mediated intravascular hemolysis while preserving C3b-mediated opsonophagocytosis; accept increased susceptibility to Neisseria meningitidis, with opsonization and immune complex clearance largely intact. Prefer C3 inhibition for Patient Y to block C3b deposition and splenic clearance; anticipate broader susceptibility to encapsulated bacteria and impaired immune complex clearance.\n\nB. Prefer C3 inhibition for Patient X to fully suppress complement and thereby prevent hemolysis; expect infectious risk to be largely limited to Neisseria due to loss of MAC, with opsonophagocytosis otherwise preserved. Prefer C5 inhibition for Patient Y to reduce extravascular opsonization with minimal infection risk.\n\nC. Prefer C5 inhibition for Patient Y because it prevents C3b deposition while retaining anaphylatoxin signaling; the main adverse effect is a higher risk of immune complex–mediated diseases due to impaired clearance. Prefer C3 inhibition for Patient X to spare MAC and avoid bacterial infections.\n\nD. Prefer C3 inhibition for Patient Y but anticipate primarily selective loss of C5a with preserved C3b opsonization; risk is chiefly attenuated neutrophil chemotaxis without increased infections by encapsulated bacteria. Prefer C5 inhibition for Patient X to reduce intravascular hemolysis with no meaningful infectious risk.\n\nE. Prefer C5 inhibition for Patient X to prevent intravascular hemolysis, but anticipate profound impairment of viral neutralization due to loss of C3b, with minimal bacterial risk. Prefer C3 inhibition for Patient Y to reduce extravascular opsonization while preserving MAC formation and resistance to Neisseria.", "solution": "The problem statement is subjected to validation.\n\n**Step 1: Extract Givens**\n- **Patient X:** Diagnosis of Paroxysmal Nocturnal Hemoglobinuria (PNH) with evidence of intravascular hemolysis. Flow cytometry indicates loss of complement regulators CD55 and CD59 on erythrocytes.\n- **Patient Y:** Diagnosis of an autoimmune hemolytic process characterized by extravascular clearance of red blood cells. The mechanism is stated to be complement opsonization. Laboratory findings include a positive Direct Antiglobulin Test (DAT) for C3d on erythrocytes and evidence of increased splenic macrophage uptake of C3b-coated cells.\n- **Therapeutic Options:** Inhibition of complement component C3 versus inhibition of complement component C5.\n- **Objective:** Determine the optimal therapeutic strategy for each patient and predict the differential infectious and immunopathologic risks.\n- **Governing Principles (provided as foundational definitions):**\n    1.  Cleavage of C3 produces the opsonin C3b and the anaphylatoxin C3a.\n    2.  Cleavage of C5 initiates the assembly of the Membrane Attack Complex (MAC) via C5b-C9, which leads to direct cellular lysis.\n    3.  Cleavage of C5 also produces C5a, a potent chemoattractant.\n\n**Step 2: Validate Using Extracted Givens**\nThe problem is scientifically grounded. The clinical scenarios described for Patient X (PNH) and Patient Y (complement-mediated autoimmune hemolytic anemia) are accurate representations of real-world pathologies. PNH pathophysiology is correctly linked to the loss of regulators like CD55 and CD59, leading to MAC-mediated intravascular hemolysis. The description of Patient Y's condition, with C3b-mediated opsonization leading to extravascular hemolysis by splenic macrophages, is a classic mechanism of autoimmune hemolysis. The foundational definitions of C3 and C5 function are a correct, albeit simplified, summary from immunology.\n\nThe problem is well-posed. It provides two distinct clinical cases and a clear set of rules (the foundational definitions) from which to deduce the most logical therapeutic intervention and its consequences. It asks for a comparative analysis, which is a standard format for problems in clinical reasoning. The problem is self-contained and does not contain contradictory information. All terms are Eobjective and clearly defined within the context of immunology.\n\n**Step 3: Verdict and Action**\nThe problem statement is valid. A solution will be derived based on the provided principles.\n\n**Derivation of Solution**\n\nThe complement system has two principal effector pathways relevant to this problem:\n1.  **Opsonization for Phagocytosis:** Mediated primarily by the deposition of C3b on a target surface.\n2.  **Terminal Cytolysis:** Mediated by the formation of the Membrane Attack Complex (MAC, composed of C5b-C9).\n\nThe cascade is sequential: activation leads to the formation of a C3 convertase, which cleaves C3 into C3a and C3b. The C3b component can then participate in forming a C5 convertase, which cleaves C5 into C5a and C5b. C5b initiates MAC formation. Therefore, inhibition of C3 will block all downstream events, including both C3b-mediated opsonization and MAC-dependent lysis. Inhibition of C5 is more distal; it will block only MAC formation and C5a generation, while preserving the upstream functions of C3b and C3a.\n\n**Analysis of Patient X (PNH):**\nThe pathology is specified as **intravascular hemolysis**. The erythrocytes lack protective proteins (CD55 and CD59), making them susceptible to attack by the complement system. Based on the provided definitions, direct cell lysis is caused by the MAC. Therefore, the primary therapeutic goal is to prevent MAC formation. Inhibition of C5 cleavage directly blocks the initial step of MAC assembly (formation of C5b) and is the most targeted approach to prevent intravascular hemolysis. This strategy preserves upstream complement functions, including the generation of the opsonin C3b. The primary adverse effect of C5 inhibition is the loss of MAC-mediated bactericidal activity, which is particularly critical for defense against Neisseria species, most notably *Neisseria meningitidis*.\n\n**Analysis of Patient Y (Autoimmune Hemolytic Anemia):**\nThe pathology is specified as **extravascular clearance** via **complement opsonization**, with splenic macrophages taking up **C3b-coated cells**. This pathology is driven by the opsonin C3b, not by the MAC. The therapeutic goal is to prevent the opsonization of erythrocytes with C3b. Therefore, the logical intervention is to inhibit C3 cleavage. This prevents the formation of C3b, thereby halting the signal for phagocytosis by splenic macrophages. C5 inhibition would be ineffective, as it would not stop the deposition of C3b. The consequence of C3 inhibition is a profound and broad complement deficiency. The loss of C3b severely impairs opsonophagocytosis, leading to increased susceptibility to a wide range of encapsulated bacteria. Furthermore, C3b is essential for the clearance of immune complexes; its absence increases the risk of immune complex-mediated diseases.\n\n**Evaluation of Options**\n\n**A. Prefer C5 inhibition for Patient X to prevent MAC-mediated intravascular hemolysis while preserving C3b-mediated opsonophagocytosis; accept increased susceptibility to Neisseria meningitidis, with opsonization and immune complex clearance largely intact. Prefer C3 inhibition for Patient Y to block C3b deposition and splenic clearance; anticipate broader susceptibility to encapsulated bacteria and impaired immune complex clearance.**\n- For Patient X: This statement correctly identifies C5 inhibition as the targeted therapy for MAC-mediated lysis, correctly notes the preservation of C3b functions (opsonization, immune complex clearance), and correctly identifies the specific risk of *Neisseria* infection.\n- For Patient Y: This statement correctly identifies C3 inhibition as the appropriate therapy to block C3b-mediated opsonization and correctly predicts the consequences of broad complement blockade: susceptibility to encapsulated bacteria and impaired immune complex clearance.\n- **Verdict: Correct.**\n\n**B. Prefer C3 inhibition for Patient X to fully suppress complement and thereby prevent hemolysis; expect infectious risk to be largely limited to Neisseria due to loss of MAC, with opsonophagocytosis otherwise preserved. Prefer C5 inhibition for Patient Y to reduce extravascular opsonization with minimal infection risk.**\n- For Patient X: This is incorrect. C3 inhibition would cripple opsonophagocytosis, contrary to the claim that it is \"preserved\". The infectious risk would be broad, not \"largely limited to *Neisseria*\".\n- For Patient Y: This is incorrect. C5 inhibition does not affect C3b deposition and therefore would not reduce extravascular opsonization.\n- **Verdict: Incorrect.**\n\n**C. Prefer C5 inhibition for Patient Y because it prevents C3b deposition while retaining anaphylatoxin signaling; the main adverse effect is a higher risk of immune complex–mediated diseases due to impaired clearance. Prefer C3 inhibition for Patient X to spare MAC and avoid bacterial infections.**\n- For Patient Y: This is incorrect. C5 inhibition does not prevent C3b deposition. Impaired immune complex clearance is a hallmark of C3 deficiency, not C5 deficiency.\n- For Patient X: This is incorrect. C3 inhibition prevents the formation of the C5 convertase, thus it absolutely does not \"spare MAC\". It would cause, not avoid, bacterial infections.\n- **Verdict: Incorrect.**\n\n**D. Prefer C3 inhibition for Patient Y but anticipate primarily selective loss of C5a with preserved C3b opsonization; risk is chiefly attenuated neutrophil chemotaxis without increased infections by encapsulated bacteria. Prefer C5 inhibition for Patient X to reduce intravascular hemolysis with no meaningful infectious risk.**\n- For Patient Y: This is incorrect. C3 inhibition makes the formation of C3b impossible. The claim that C3b opsonization is \"preserved\" is a direct contradiction. Consequently, the claim of no increased risk of infection from encapsulated bacteria is false.\n- For Patient X: This is incorrect. C5 inhibition carries a well-established, clinically significant risk of meningococcal disease. The statement \"no meaningful infectious risk\" is false.\n- **Verdict: Incorrect.**\n\n**E. Prefer C5 inhibition for Patient X to prevent intravascular hemolysis, but anticipate profound impairment of viral neutralization due to loss of C3b, with minimal bacterial risk. Prefer C3 inhibition for Patient Y to reduce extravascular opsonization while preserving MAC formation and resistance to Neisseria.**\n- For Patient X: This is incorrect. C5 inhibition preserves C3b, it does not cause its loss. The bacterial risk is not minimal.\n- For Patient Y: This is incorrect. C3 inhibition prevents MAC formation because C3b is a necessary component of the C5 convertase.\n- **Verdict: Incorrect.**\n\nBased on a rigorous application of the provided principles, only option A provides a logically and immunologically sound analysis for both patients.", "answer": "$$\\boxed{A}$$", "id": "2836510"}]}